Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's Second-largest CRO Seeks Initial Public Offering In The U.S.

This article was originally published in PharmAsia News

Executive Summary

Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18

You may also be interested in...

ShangPharma Biologics Head Mitchell Reff On Biologics R&D In China: An Interview With PharmAsia News

ShangPharma’s new Chief Biologic Officer Mitchell Reff discusses the company’s expansion into biologics and his views on biologics development in China.

Will WuXi Benefit From Rival ShangPharma Going Private?

China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.

Chinese CRO ShangPharma Opens New Facility To Support Lilly's Pipeline

China’s second-largest CRO opens new Shanghai facility to support its largest client.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts